Our work for the first time defines a pathway in HG-SOC that is associated with and appears to drive the biological and clinical behaviour of a distinct molecular subtype of ovarian cancer, suggesting a targeted therapeutic approach in this group of patients. This evidence concerns the gene UBXN11 and ovarian cancer.